Table 4.
Hazard ratios and 95% confidence intervals for cause-specific sick leave
| Treatment | Cause-specific sick leave | |||||
|---|---|---|---|---|---|---|
| Month 6 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
| HRa (95% CI) | HRa (95% CI) | HRa (95% CI) | HRa (95% CI) | HRa (95% CI) | HRa (95% CI) | |
| Sick leave due to depression or anxiety | ||||||
| Chemotherapy | ||||||
| No | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Yes | 1.04 (0.77–1.42) | 1.09 (0.83–1.42) | 1.14 (0.83–1.58) | 1.25 (0.97–1.61) | 1.38 (1.05–1.80) | 1.50 (1.05–2.14) |
| Radiotherapy (RT) | ||||||
| Mastectomy only | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Mastectomy + RT | 0.85 (0.52–1.38) | 0.96 (0.66–1.41) | 1.10 (0.71–1.72) | 1.06 (0.76–1.49) | 0.99 (0.70–1.41) | 0.94 (0.57–1.55) |
| BCS + RT | 0.73 (0.50–1.07) | 0.83 (0.61–1.13) | 0.95 (0.66–1.39) | 0.97 (0.74–1.29) | 0.98 (0.73–1.31) | 0.99 (0.66–1.49) |
| Endocrine therapyb | ||||||
| No | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Yes | 1.65 (1.05–2.61) | 1.69 (1.12–2.57) | 1.72 (1.06–2.77) | 1.62 (1.08–2.45) | 1.52 (0.99–2.33) | 1.44 (0.84–2.44) |
| Sick leave due to cancer | ||||||
| Chemotherapy | ||||||
| No | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Yes | 1.97 (1.70–2.28) | 1.80 (1.63–2.00) | 1.68 (1.53–1.85) | 1.63 (1.48–1.80) | 1.61 (1.45–1.78) | 1.60 (1.44–1.77) |
| Radiotherapy (RT) | ||||||
| Mastectomy only | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Mastectomy + RT | 1.69 (1.38–2.07) | 1.51 (1.30–1.74) | 1.37 (1.17–1.61) | 1.31 (1.10–1.58) | 1.29 (1.05–1.57) | 1.27 (1.03–1.57) |
| BCS + RT | 1.57 (1.31–1.87) | 0.98 (0.87–1.11) | 0.55 (0.47–0.64) | 0.37 (0.29–0.47) | 0.29 (0.21–0.40) | 0.24 (0.16–0.36) |
| Endocrine therapyb | ||||||
| No | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Yes | 0.87 (0.72–1.05) | 0.94 (0.82–1.07) | 0.98 (0.87–1.12) | 1.00 (0.88–1.15) | 1.01 (0.88–1.17) | 1.02 (0.88–1.18) |
| Sick leave due to other reasons | ||||||
| Chemotherapy | ||||||
| No | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Yes | 1.03 (0.87–1.22) | 1.07 (0.94–1.23) | 1.11 (0.96–1.28) | 1.09 (0.96–1.24) | 1.04 (0.90–1.20) | 1.01 (0.85–1.20) |
| Radiotherapy (RT) | ||||||
| Mastectomy only | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Mastectomy + RT | 0.77 (0.60–0.99) | 0.93 (0.78–1.10) | 1.06 (0.89–1.27) | 1.10 (0.93–1.29) | 1.05 (0.88–1.25) | 1.00 (0.80–1.25) |
| BCS + RT | 0.53 (0.43–0.64) | 0.56 (0.49–0.65) | 0.61 (0.52–0.71) | 0.67 (0.59–0.77) | 0.74 (0.64–0.85) | 0.77 (0.64–0.93) |
| Endocrine therapyb | ||||||
| No | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Yes | 1.05 (0.84–1.32) | 1.18 (0.98–1.42) | 1.26 (1.03–1.53) | 1.26 (1.04–1.52) | 1.20 (0.97–1.46) | 1.14 (0.90–1.46) |
BCS breast-conserving therapy, RT radiotherapy
aHazard ratios were adjusted for chemotherapy, radiotherapy/surgery, endocrine therapy, tumor size, lymph node involvement, axillary lymph node dissection, ER status, age at diagnosis, level of education, prior sick leave, region of residency, calendar year of diagnosis, and medical history of mental disorders. The underlying time-scale was time since diagnosis
bInitiation of endocrine therapy